[go: up one dir, main page]

DE69930624D1 - Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie - Google Patents

Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie

Info

Publication number
DE69930624D1
DE69930624D1 DE69930624T DE69930624T DE69930624D1 DE 69930624 D1 DE69930624 D1 DE 69930624D1 DE 69930624 T DE69930624 T DE 69930624T DE 69930624 T DE69930624 T DE 69930624T DE 69930624 D1 DE69930624 D1 DE 69930624D1
Authority
DE
Germany
Prior art keywords
trackataxie
backstrain
atx
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69930624T
Other languages
English (en)
Other versions
DE69930624T2 (de
Inventor
Toru Nishikawa
Keji Wada
Yasuyuki Ichimaru
Aiko Sawa
Toyokazu Hiranuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of DE69930624D1 publication Critical patent/DE69930624D1/de
Publication of DE69930624T2 publication Critical patent/DE69930624T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69930624T 1998-06-10 1999-06-03 Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie Expired - Fee Related DE69930624T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16165398 1998-06-10
JP16165398 1998-06-10
PCT/JP1999/002971 WO1999063989A1 (fr) 1998-06-10 1999-06-03 Traitements de l'ataxie spinocerebelleuse et compositions utiles pour traiter l'ataxie spinocerebelleuse

Publications (2)

Publication Number Publication Date
DE69930624D1 true DE69930624D1 (de) 2006-05-18
DE69930624T2 DE69930624T2 (de) 2006-09-14

Family

ID=15739283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930624T Expired - Fee Related DE69930624T2 (de) 1998-06-10 1999-06-03 Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie

Country Status (7)

Country Link
US (1) US7067545B1 (de)
EP (1) EP1084704B1 (de)
JP (1) JP3363440B2 (de)
AT (1) ATE321553T1 (de)
DE (1) DE69930624T2 (de)
ES (1) ES2262322T3 (de)
WO (1) WO1999063989A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1695703T3 (da) 2000-08-25 2010-10-25 Res Corp Technologies Inc Nye anvendelser for aminosyrekrampestillende midler
AU2002311784B2 (en) 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
JP5196641B2 (ja) * 2004-09-09 2013-05-15 塩野義製薬株式会社 脊髄小脳変性症治療剤
TWI350754B (en) 2004-09-09 2011-10-21 Shionogi & Co A pharmaceutical composition for treating spinocerebellar ataxia
RU2537187C2 (ru) * 2009-09-14 2014-12-27 Сисейдо Компани,Лтд. Композиция для уменьшения повреждения, вызванного уф-излучением
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
JPH0826986A (ja) * 1994-07-21 1996-01-30 Yamanouchi Pharmaceut Co Ltd 抗フェンサイクリジン薬
DE19612823C2 (de) 1995-03-31 2001-03-01 Mitsubishi Chem Corp Optisches Aufzeichnungsverfahren
TW372314B (en) 1996-11-25 1999-10-21 Hitachi Maxell Data recording medium and data regeneration apparatus thereof
DE69837168T2 (de) 1997-03-27 2007-10-31 Mitsubishi Kagaku Media Co. Ltd. Optisches Informationsaufzeichnungsmedium

Also Published As

Publication number Publication date
US7067545B1 (en) 2006-06-27
JP3363440B2 (ja) 2003-01-08
ATE321553T1 (de) 2006-04-15
DE69930624T2 (de) 2006-09-14
EP1084704A4 (de) 2003-07-23
WO1999063989A1 (fr) 1999-12-16
EP1084704A1 (de) 2001-03-21
ES2262322T3 (es) 2006-11-16
EP1084704B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
DE60117043D1 (de) Behandlung von mukositis
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
PT1001775E (pt) Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil
BRPI0407178A (pt) Composição farmacêutica osteogênica
DE69930624D1 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
ATE183648T1 (de) Arzneimittel enthaltend mischungen von höheren primären aliphatischen alkoholen zur behandlung von hypercholesterolämie und hyperlipoproteinämie typ ii und zur stimulation des sexuellen verhaltens bei tieren und menschen
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE454896T1 (de) Heilkräuterzusammensetzung zur behandlung von aids
ATE131729T1 (de) 3,5-diiod-l-thyronin zur tsh-suppression und behandlung von struma
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
WO2004052331A3 (fr) Utilisation d'un extrait de miellat de coton comme ingredient acitif

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: RECHTS- UND PATENTANWAELTE LORENZ SEIDLER GOSSEL,

8339 Ceased/non-payment of the annual fee